Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate / 中华医学杂志(英文版)

ABSTRACT

Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.